134 related articles for article (PubMed ID: 12602899)
1. Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: a GEICAM-9801 phase II study.
Alba E; Ribelles N; Antón A; Pérez-Carrión R; López-Vega JM; Llanos M; Pelegri A; Florián J; Menéndez M; Godes MJ;
Breast Cancer Res Treat; 2003 Jan; 77(1):1-8. PubMed ID: 12602899
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
3. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.
Khayat D; Chollet P; Antoine EC; Monfardini S; Ambrosini G; Benhammouda A; Mazen MF; Sorio R; Borg-Olivier O; Riva A; Ramazeilles C; Azli N
J Clin Oncol; 2001 Jul; 19(14):3367-75. PubMed ID: 11454884
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.
Sparano JA; O'Neill A; Schaefer PL; Falkson CI; Wood WC
J Clin Oncol; 2000 Jun; 18(12):2369-77. PubMed ID: 10856096
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer.
Aihara T; Takatsuka Y; Itoh K; Sasaki Y; Katsumata N; Watanabe T; Noguchi S; Horikoshi N; Tabei T; Sonoo H; Hiraki S; Inaji H
Oncology; 2003; 64(2):124-30. PubMed ID: 12566909
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer.
Palmeri S; Leonardi V; Tamburo De Bella M; Morabito A; Vaglica M; Accurso V; Ferraù F; Failla G; Agostara B; Massidda B; Valenza R; Fanelli M; Gasparini G
Oncology; 2002; 63(3):205-12. PubMed ID: 12381898
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
Alexopoulos A; Kouroussis C; Malamos N; Kakolyris S; Kalbakis K; Kosmas C; Mavroudis D; Agelaki S; Vlachonicolis J; Sarra E; Rigatos G; Georgoulias V
Ann Oncol; 2001 Jun; 12(6):793-8. PubMed ID: 11484954
[TBL] [Abstract][Full Text] [Related]
10. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
Gómez-Bernal A; Cruz JJ; Olaverri A; Arizcun A; Martín T; Rodríguez CA; Martín G; Fonseca E; Sánchez P
Anticancer Drugs; 2005 Jan; 16(1):77-82. PubMed ID: 15613908
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
Sparano JA; Malik U; Rajdev L; Sarta C; Hopkins U; Wolff AC
J Clin Oncol; 2001 Jun; 19(12):3117-25. PubMed ID: 11408509
[TBL] [Abstract][Full Text] [Related]
12. High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
Milla-Santos A; Milla L; Rallo L; Solano V
Am J Clin Oncol; 2001 Apr; 24(2):138-42. PubMed ID: 11319287
[TBL] [Abstract][Full Text] [Related]
13. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
Kouroussis C; Androulakis N; Kakolyris S; Souglakos J; Kotsakis T; Mavroudis D; Katsogridakis K; Vardakis N; Hatzidaki D; Samonis G; Vlachonikolis J; Georgoulias V
J Clin Oncol; 1999 Mar; 17(3):862-9. PubMed ID: 10071277
[TBL] [Abstract][Full Text] [Related]
14. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.
Misset JL; Dieras V; Gruia G; Bourgeois H; Cvitkovic E; Kalla S; Bozec L; Beuzeboc P; Jasmin C; Aussel JP; Riva A; Azli N; Pouillart P
Ann Oncol; 1999 May; 10(5):553-60. PubMed ID: 10416005
[TBL] [Abstract][Full Text] [Related]
15. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Pagani O; Sessa C; Nolè F; Crivellari D; Lombardi D; Thürlimann B; Hess D; Borner M; Bauer J; Martinelli G; Graffeo R; Zucchetti M; D'Incalci M; Goldhirsch A
Ann Oncol; 2000 Aug; 11(8):985-91. PubMed ID: 11038035
[TBL] [Abstract][Full Text] [Related]
16. Preliminary results of multicenter phase II trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer.
Muthalib A; Darwis I; Prayogo N; Sutjipto
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():498-504. PubMed ID: 10895201
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Nabholtz JM; Smylie M; Mackey J; Paterson A; Noel D; al-Tweigeri ; Janowska A; Delorme F; Riva A
Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):25-7. PubMed ID: 9213324
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Perez EA; Geeraerts L; Suman VJ; Adjei AA; Baron AT; Hatfield AK; Maihle N; Michalak JC; Kuross SA; Kugler JW; Lafky JM; Ingle JN
Ann Oncol; 2002 Aug; 13(8):1225-35. PubMed ID: 12181246
[TBL] [Abstract][Full Text] [Related]
19. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
20. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group.
Miller KD; McCaskill-Stevens W; Sisk J; Loesch DM; Monaco F; Seshadri R; Sledge GW
J Clin Oncol; 1999 Oct; 17(10):3033-7. PubMed ID: 10506597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
